Search form


Press Releases

Axcan Pharma to host Analyst/Investor Luncheons in Toronto and New-York

Feb 18, 2005 - 12:00 ET

MONT SAINT-HILAIRE, Quebec, Feb. 18 - Axcan Pharma Inc.
("Axcan" or the "Company") announced today its upcoming Analyst/Investor
Luncheons in Toronto (February 22, 2005) and New-York (February 24, 2005).
Léon F. Gosselin, President and Chief Executive Officer of Axcan, and
David W. Mims, Executive Vice President and Chief Operating Officer of the
Company, will give a corporate overview followed by a question and answer
The luncheons will also feature Dr. François Martin, Senior Vice
President, Scientific Affairs of Axcan and Dr. Patrick Colin, Vice President,
Research and Development, who will discuss various development programs in
Axcan's pipeline.
An audio webcast will be available live on the Axcan website at .

Axcan is a leading specialty pharmaceutical company involved in the field
of gastroenterology. The Company markets a broad line of prescription products
sold for the treatment of symptoms in a number of gastrointestinal diseases
and disorders such as inflammatory bowel disease, irritable bowel syndrome,
cholestatic liver diseases and complications related to cystic fibrosis.
Axcan's products are marketed by its own sales force in North America and
Europe. Its common shares are listed on the Toronto Stock Exchange under the
symbol "AXP" and on the NASDAQ National Market under the symbol "AXCA".

Julie M. Thibodeau, Manager, Investor 
Relations, Axcan Pharma Inc., (450) 467-5138, ext. 2062;; 
Source: Axcan Pharma Inc.